Let me start with a sentence that would have sounded strange five years ago. A Nigerian musician who made his name with Afrobeats hits is now one of the largest shareholders in a Ghanaian pharmaceutical company that makes intravenous fluids and life-saving saline solutions. Oluwatosin “Mr Eazi” Ajibade, through his investment firm Zagadat Capital, has acquired a 17.31 percent stake in Intravenous Infusions PLC, a local manufacturer listed on the Ghana Alternative Exchange. The transaction involved 47.5 million shares, making it one of the largest single-block purchases on the GAX in recent years. And the message it sends is simple. Smart money now believes that Ghana can manufacture its own essential medicines, not just import them.
Let me break down what happened and why it matters. Zagadat Capital GH Ltd, where Mr Eazi serves as Chief Investment Officer, executed a series of open-market purchases through licensed dealing member Laurus Africa Securities. The acquisition was disclosed in a regulatory filing on May 18, 2026, in compliance with the Securities Industry Act and Ghana Stock Exchange rules. The firm now holds 17.31 percent of IIL’s issued shares, making it a significant minority shareholder. Zagadat Capital was careful to clarify that the equity purchase is not intended to trigger a corporate takeover or destabilise the company’s current administrative control. Instead, they described it as a deliberate, long-term investment strategy aimed at expanding the domestic healthcare supply chain, reflecting a firm belief in the commercial viability of local medicine production.
Why does this matter? Because Ghana, like most African countries, has been dangerously dependent on imported pharmaceuticals. Before local manufacturers like IIL emerged, almost all intravenous fluids, saline solutions, and essential medicines came from abroad, primarily from India, China, and Europe. The COVID-19 pandemic exposed the fragility of that dependence. When global supply chains were disrupted, hospitals faced shortages of basic supplies. Patients could not get the drips they needed. Doctors had to ration. It was a wake-up call. Since then, the government has implemented policies to encourage local manufacturing, including tax incentives, preferential procurement, and support for the Food and Drugs Authority to fast-track approvals. But policies alone do not build factories. Capital does. And that is where Zagadat Capital comes in.
Intravenous Infusions PLC is not a new company. It has been operating for years, producing vital intravenous fluids, saline solutions, and other pharmaceutical formulations. But it has been constrained by limited capital. Expanding production, upgrading equipment, and meeting growing demand all require investment. The company’s 2025 annual report highlighted operational resilience and a commitment to serving the West African healthcare ecosystem. But resilience is not enough. Growth requires fuel. Zagadat Capital’s investment provides that fuel, not directly through a capital raise, the shares were purchased on the open market, so the money went to selling shareholders, not the company. But the increased liquidity and the signal effect, a serious investment firm sees value in IIL, may attract other investors and support future capital raising.
The involvement of Mr Eazi has attracted attention, and rightly so. He is best known for his music and for emPawa Africa, an initiative that supports emerging African artists. But he has also built a reputation as a tech and business investor, backing startups across the continent. His role as Chief Investment Officer of Zagadat Capital signals that the firm is serious about deploying capital in strategic African industries, not just in technology and entertainment. Pharmaceuticals are not glamorous. Intravenous fluids are not exciting. But they are essential. And that is exactly the kind of business that patient, long-term capital should back.
Let me also talk about the Ghana Alternative Exchange, where IIL is listed. The GAX was established to provide a platform for smaller, growth-oriented companies that may not meet the stricter listing requirements of the main Ghana Stock Exchange. However, the GAX has struggled with low liquidity and limited investor interest. Many companies list and then trade infrequently, if at all. The IIL transaction, involving 47.5 million shares, is a significant exception. It demonstrates that the GAX can support meaningful capital flows and that investors are willing to take significant stakes in GAX-listed companies. That is a vote of confidence not just in IIL, but in the exchange itself.
The import substitution potential is significant. Ghana spends an estimated 500 million to 700 million dollars annually on imported pharmaceuticals. Substituting locally produced products for imports would save foreign exchange, create jobs, and improve health security. IIL’s intravenous fluids and saline solutions are products that can be produced competitively in Ghana. The technology is not exotic. The raw materials, water, salt, sugar, and packaging, are available locally. The market is large and growing. The missing piece has been investment at scale. Zagadat Capital is providing that.
But let me also be realistic. One investment does not transform a sector. The pharmaceutical manufacturing industry in Ghana faces significant challenges. Local producers must compete with imports that may be subsidised by foreign governments or produced at much larger scale, giving them cost advantages. The regulatory environment, while improving, can still be slow and unpredictable. And the government’s commitment to preferential procurement, giving local manufacturers an advantage in public tenders, must be implemented consistently. Zagadat Capital’s due diligence would have assessed these factors. Their decision to invest suggests they believe the risks are manageable and the returns are attractive.
The acquisition also has implications for corporate governance. IIL is a listed company. Its financial statements are public. Its board is accountable. Its shares are tradeable. This transparency enabled Zagadat Capital to conduct due diligence and execute the acquisition. Unlisted companies, no matter how well-managed, cannot attract the same level of investment because the information asymmetry is too great. That is a lesson for other Ghanaian businesses. If you want to attract serious capital, consider listing. The process is demanding, but the rewards include access to a wider pool of investors, improved governance, and a market valuation that reflects your performance.
The involvement of a Nigerian investment firm and a Nigerian celebrity investor also underscores the regional nature of capital markets. West African integration, under ECOWAS, includes provisions for cross-border investment. The IIL acquisition is a practical example of that integration. A Nigerian firm invested in a Ghanaian company listed on a Ghanaian exchange, with the transaction executed through a licensed dealing member. No political barriers. No currency restrictions that could not be managed. No regulatory roadblocks. That is how integration is supposed to work.
So what happens next? Intravenous Infusions will continue to operate under its current management, with Zagadat Capital as a significant minority shareholder. The firm’s representatives may join the board, depending on the company’s articles of association and the willingness of existing shareholders. Any board appointment would require a vote at a general meeting. Zagadat Capital may increase its stake over time, or it may hold the 17.31 percent position as a long-term investment. The firm’s statement that the acquisition is part of a long-term strategy suggests that it is not a quick flip. However, the firm will also expect a return on its investment, either through dividends or capital appreciation.
For the broader pharmaceutical sector, the acquisition is a validation. Local manufacturers have long complained that investors do not take them seriously, preferring to invest in trading, real estate, or financial services. Zagadat Capital’s investment challenges that narrative. If IIL succeeds with its new shareholder, other pharmaceutical companies may attract similar interest. The government should capitalise on this momentum by announcing new policies to support local manufacturing, such as expanding preferential procurement, increasing funding for the FDA to speed up approvals, and providing incentives for local content in health supply chains.
For the average Ghanaian, this acquisition may seem distant. A Nigerian investor buying shares in a pharmaceutical company does not immediately put food on the table. But the ripple effects matter. A stronger pharmaceutical sector means more jobs, from factory workers to quality control technicians to logistics staff. It means lower healthcare costs, because locally produced medicines do not incur import duties or shipping fees. It means better health security, because when the next global supply chain disruption hits, Ghana will have its own supply of essential medicines. And it means more confidence in the Ghanaian economy, because when investors like Zagadat Capital put their money where their mouth is, other investors pay attention.
The Mr Eazi effect, as some are calling it, is not about celebrity. It is about signal. It says that Ghanaian manufacturing is investable. It says that the Ghana Alternative Exchange works. It says that local pharmaceutical production is not just a policy goal, but a commercial reality. That is the message. And it is a message that Ghana’s policymakers, regulators, and business leaders should amplify. Because the capital is out there. The companies are here. The only missing ingredient is the sustained, collective effort to match them. The IIL deal is a start. Let us make sure it is not the end.
